FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines ...

Novartis has claimed accelerated approval from the FDA for Vanrafia, one of a trio of therapies it hopes will revolutionise the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia ...

NICE reversed its earlier decision on sparsentan for treating primary immunoglobulin A nephropathy after additional evidence ...

Panelists discuss how patient-reported outcomes including symptom burden, treatment-related adverse effects, preserved functionality, and impact on quality of life should be prioritized alongside ...

The IgA Nephropathy drugs market is set for 18.1% CAGR growth, led by biologics, FDA approvals, and major pharma R&D efforts ...

Atacicept, an investigational BAFF (B-cell activating factor)/APRIL (a proliferation-inducing ligand) dual inhibitor, significantly reduced proteinuria in patients with immunoglobulin A nephropathy ...

Panelists discuss how early diagnosis of immunoglobulin A (IgA) nephropathy enables timely interventions that can ...

Vera Therapeutics (NASDAQ:VERA) shares surged 64% after positive late-stage trial results for atacicept in treating IgA ...